

# Dipak Kotecha, Fesc

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626707/publications.pdf>

Version: 2024-02-01

107  
papers

31,698  
citations

61984

43  
h-index

32842

100  
g-index

116  
all docs

116  
docs citations

116  
times ranked

21620  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.   | 1.7  | 370       |
| 2  | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.   | 1.8  | 220       |
| 3  | A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.  | 7.1  | 14        |
| 4  | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.  | 7.1  | 820       |
| 5  | Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 1600-1607.  | 2.9  | 15        |
| 6  | Identification and Mapping Real-World Data Sources for Heart Failure, Acute Coronary Syndrome, and Atrial Fibrillation. <i>Cardiology</i> , 2022, 147, 98-106.   | 1.4  | 9         |
| 7  | Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.   | 2.2  | 14        |
| 8  | Cardiac Imaging to Assess Left Ventricular Systolic Function in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 139, 40-49.   | 1.6  | 5         |
| 9  | 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.                                   | 2.2  | 5,583     |
| 10 | Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599. | 2.0  | 4         |
| 11 | Transforming clinical research by involving and empowering patients—the RATE-AF randomized trial. <i>European Heart Journal</i> , 2021, 42, 2411-2414.   | 2.2  | 8         |
| 12 | Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 902-908.  | 2.9  | 7         |
| 13 | Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. <i>BMC Medicine</i> , 2021, 19, 85.  | 5.5  | 33        |
| 14 | Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1681.  | 7.4  | 1         |
| 15 | Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003599.   | 8.4  | 16        |
| 16 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.  | 2.2  | 2,517     |
| 17 | Redefining $\beta$ -blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. <i>Lancet, The</i> , 2021, 398, 1427-1435.  | 13.7 | 52        |
| 18 | Quality and Completeness of Myocardial Infarction Recording in Clinical Practice Research Datalink Aurum. <i>Clinical Epidemiology</i> , 2021, Volume 13, 745-753.   | 3.0  | 14        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.   | 2.2 | 899       |
| 20 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.  | 2.2 | 5,558     |
| 21 | Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.  | 1.7 | 38        |
| 22 | Response to the Letter from Dr. Wei Hui, Regarding the Recent Publication of "A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements". Journal of the American Society of Echocardiography, 2020, 33, 1293.                | 2.8 | 1         |
| 23 | ESC Core Curriculum for the Cardiologist. European Heart Journal, 2020, 41, 3605-3692.  | 2.2 | 38        |
| 24 | Importance and Assessment of Quality of Life in Symptomatic Permanent Atrial Fibrillation: Patient Focus Groups from the RATE-AF Trial. Cardiology, 2020, 145, 666-675.   | 1.4 | 9         |
| 25 | Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Medicine, 2020, 18, 103.  | 5.5 | 40        |
| 26 | STEEER-AF: a cluster-randomized education trial from the ESC. European Heart Journal, 2020, 41, 1952-1954.  | 2.2 | 9         |
| 27 | Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. Europace, 2020, 22, 748-760.  | 1.7 | 72        |
| 28 | Longitudinal Assessment of Cardiac Involvement in Fabry Disease Using Cardiovascular Magnetic Resonance Imaging. JACC: Cardiovascular Imaging, 2020, 13, 1850-1852.   | 5.3 | 5         |
| 29 | Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. JAMA - Journal of the American Medical Association, 2020, 324, 2497.   | 7.4 | 118       |
| 30 | Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. Europace, 2019, 21, 1776-1784.   | 1.7 | 22        |
| 31 | A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements. Journal of the American Society of Echocardiography, 2019, 32, 1505-1515.  | 2.8 | 98        |
| 32 | Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. Systematic Reviews, 2019, 8, 221.   | 5.3 | 2         |
| 33 | Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?. European Journal of Heart Failure, 2019, 21, 480-481.   | 7.1 | 0         |
| 34 | Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?. European Heart Journal, 2019, 41, 652-654a.  | 2.2 | 9         |
| 35 | A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RailRoAD) compared with current standard practice. Trials, 2019, 20, 314. | 1.6 | 6         |
| 36 | Education as a vehicle towards quality improvement in the European Society of Cardiology. Cardiovascular Research, 2019, 115, e80-e81.  | 3.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open, 2019, 9, e022478. | 1.9 | 50        |
| 38 | B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. BMC Medicine, 2019, 17, 72.  | 5.5 | 14        |
| 39 | Digital learning and the future cardiologist. European Heart Journal, 2019, 40, 499-501.   | 2.2 | 14        |
| 40 | Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace, 2019, 21, 746-753.  | 1.7 | 39        |
| 41 | 10-...A simple method to improve the reliability of echocardiography in patients with atrial fibrillation. , 2019, , .   |     | 0         |
| 42 | Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart, 2019, 105, 1825-1831.   | 2.9 | 15        |
| 43 | Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.  | 2.8 | 39        |
| 44 | All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. American Journal of Therapeutics, 2019, 26, e671-e678.               | 0.9 | 6         |
| 45 | Effects of blood pressure-lowering drugs in heart failure. Journal of Hypertension, 2019, 37, 1757-1767.   | 0.5 | 7         |
| 46 | Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.  | 2.2 | 8         |
| 47 | Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. European Heart Journal, 2019, 40, 1268-1276.   | 2.2 | 96        |
| 48 | The future of continuing medical education: the roles of medical professional societies and the health care industry. European Heart Journal, 2019, 40, 1720-1727.   | 2.2 | 11        |
| 49 | Incidence and clinical implications of intraoperative bilateral internal thoracic artery graft conversion: Insights from the Arterial Revascularization Trial. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2346-2355.e6.  | 0.8 | 28        |
| 50 | Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial). Journal of the American Heart Association, 2018, 7, .   | 3.7 | 10        |
| 51 | Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. European Heart Journal, 2018, 39, 1481-1495.   | 2.2 | 163       |
| 52 | Totally thoracoscopic ablation for atrial fibrillation: a systematic safety analysis. Europace, 2018, 20, 1790-1797.   | 1.7 | 45        |
| 53 | European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. Europace, 2018, 20, 225-233.  | 1.7 | 97        |
| 54 | Reply. Journal of the American College of Cardiology, 2018, 71, 105.   | 2.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.  | 1.7 | 95        |
| 56 | Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.                              | 1.7 | 38        |
| 57 | Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35. | 2.2 | 426       |
| 58 | Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. <i>Europace</i> , 2018, 20, f153-f161.   | 1.7 | 80        |
| 59 | Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1984-1986.                               | 2.8 | 18        |
| 60 | Thoracoscopic Left Atrial Appendage Clipping. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 893-901.  | 3.2 | 42        |
| 61 | Co-morbidity (HFrEF and HFpEF): atrial fibrillation. , 2018, , 1797-1801.  |     | 2         |
| 62 | Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.   | 2.9 | 104       |
| 63 | Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017, 6, .  | 3.7 | 187       |
| 64 | Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.   | 2.8 | 198       |
| 65 | Observational Versus Randomized. <i>JACC: Heart Failure</i> , 2017, 5, 395-396.  | 4.1 | 0         |
| 66 | Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. <i>Europace</i> , 2017, 19, 1427-1438.   | 1.7 | 48        |
| 67 | 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 50.  | 0.6 | 280       |
| 68 | Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2017, 22, 731-741.  | 3.9 | 98        |
| 69 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.   | 1.9 | 37        |
| 70 | ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017, 38, 2643-2645.   | 2.2 | 9         |
| 71 | Neurohormonal Blockade in Heart Failure. <i>Cardiac Failure Review</i> , 2017, 03, 19.   | 3.0 | 53        |
| 72 | 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH EACTS. <i>Russian Journal of Cardiology</i> , 2017, , 7-86.  | 1.4 | 87        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Digoxin: The good and the bad. Trends in Cardiovascular Medicine, 2016, 26, 585-595.   | 4.9 | 102       |
| 74 | Letter: Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients – Response. International Journal of Cardiology, 2016, 214, 516-517.                        | 1.7 | 0         |
| 75 | Magnesium for Atrial Fibrillation, Myth or Magic?. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .   | 4.8 | 12        |
| 76 | Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy. Circulation: Cardiovascular Imaging, 2016, 9, .   | 2.6 | 86        |
| 77 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.  | 1.4 | 754       |
| 78 | Authors’ reply to Cunningham and Messerli and colleagues. BMJ, The, 2016, 353, i3141.  | 6.0 | 0         |
| 79 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.  | 2.2 | 5,689     |
| 80 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.  | 1.7 | 3,523     |
| 81 | Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.  | 2.8 | 292       |
| 82 | What’s new in the 2016 ESC Guidelines on atrial fibrillation?. European Heart Journal, 2016, 37, 2851-2852.  | 2.2 | 2         |
| 83 | In memoriam Henry Krum, 1958-2015. Cardiology, 2016, 134, 107-108.   | 1.4 | 34        |
| 84 | Effect of age and sex on efficacy and tolerability of $\beta^2$ blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.             | 6.0 | 95        |
| 85 | Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.  | 3.3 | 37        |
| 86 | Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. International Journal of Cardiology, 2016, 203, 660-666. | 1.7 | 161       |
| 87 | A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.          | 1.7 | 121       |
| 88 | Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. PLoS ONE, 2016, 11, e0165790.  | 2.5 | 44        |
| 89 | Qualifying the Use of Common Cardiovascular Drugs in Cardiology. Circulation Journal, 2015, 79, 517-518.   | 1.6 | 1         |
| 90 | Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. Stroke, 2015, 46, 608-609.   | 2.0 | 11        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. Stroke, 2015, 46, 2523-2528.   | 2.0  | 57        |
| 92  | 26â€¦Digoxin â€œ Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. Heart, 2015, 101, A14.2-A15.   | 2.9  | 1         |
| 93  | Î² blockers in patients with heart failure and atrial fibrillation â€œ Authors' reply. Lancet, The, 2015, 385, 1618-1619.   | 13.7 | 4         |
| 94  | Atrial fibrillation in heart failure: what should we do?. European Heart Journal, 2015, 36, ehv513.   | 2.2  | 243       |
| 95  | Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, The, 2015, 351, h4451.   | 6.0  | 247       |
| 96  | Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evidence-Based Medicine, 2014, 19, 222-223.                  | 0.6  | 17        |
| 97  | Efficacy of Î² blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243.                           | 13.7 | 475       |
| 98  | Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Systematic Reviews, 2013, 2, 7.  | 5.3  | 21        |
| 99  | Radial artery pulse wave analysis for non-invasive assessment of coronary artery disease. International Journal of Cardiology, 2013, 167, 917-924.                                      | 1.7  | 11        |
| 100 | Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm. Hypertension Research, 2013, 36, 854-855.  | 2.7  | 2         |
| 101 | Five-minute heart rate variability can predict obstructive angiographic coronary disease. Heart, 2012, 98, 395-401.   | 2.9  | 50        |
| 102 | Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. American Heart Journal, 2011, 161, 822-831.e2.  | 2.7  | 67        |
| 103 | Contemporary predictors of coronary artery disease in patients referred for angiography. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 280-288.           | 2.8  | 11        |
| 104 | Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. The Cochrane Library, 2010, , CD007613.  | 2.8  | 50        |
| 105 | Thienopyridines in Stable Coronary Disease. , 2010, , 131-141.  |      | 0         |
| 106 | Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure, 2009, 11, 872-880. | 7.1  | 85        |
| 107 | Improved Risk Prediction Using Non-Invasive Methodsâ€œThe Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study. Heart Lung and Circulation, 2008, 17, S72.               | 0.4  | 0         |